Teduglutide is approved in Europe and marketed as Revestive by Nycomed, which holds the right to develop and commercialize teduglutide outside North America.

Teduglutide is already approved in Europe and marketed as Revestive by Nycomed, which holds the right to develop and commercialize teduglutide outside North America.